{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:49:45Z","timestamp":1790880585933,"version":"4.1.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes) syndrome is a complex paraneoplastic syndrome related to a lambda-restricted low\u2013tumor burden neoplasm. The diagnosis must be considered in the context of what might otherwise be believed to be a \u201cmonoclonal gammopathy of undetermined significance,\u201d with unusual features including, but not limited to, peripheral neuropathy, thrombocytosis, and extracellular volume overload. Once a diagnosis of POEMS syndrome is made, besides very specific supportive care, the treatments resemble those of multiple myeloma or solitary plasmacytoma of the bone. Based on case series, autologous stem cell transplant is still a favored therapy with durable remissions even without maintenance therapy. Even before the era of therapeutic monoclonal antibodies, bispecific T-cell engagers, and chimeric antigen receptor antibodies, 10-year overall survival approached 80%. Patients achieving a complete hematologic response have a progression-free survival of 88% even without maintenance therapy. Herein, a case of a patient with a less-than-average outcome is described to highlight some of the long-term challenges and complexities of managing patients with POEMS syndrome.<\/jats:p>","DOI":"10.1182\/hematology.2025000729","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:08:53Z","timestamp":1764943733000},"page":"393-400","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["POEMS syndrome: diagnosis, treatments, and outcomes"],"prefix":"10.1182","volume":"2025","author":[{"given":"Angela","family":"Dispenzieri","sequence":"first","affiliation":[{"name":"Professor of Medicine and Laboratory Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"24","key":"2025120616334892400_hem2025000729C1","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1182\/blood-2010-12-328112","article-title":"Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome","volume":"117","author":"Li","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2025120616334892400_hem2025000729C2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ajh.25100","article-title":"A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome","volume":"93","author":"Li","year":"2018","journal-title":"Am J Hematol"},{"issue":"11","key":"2025120616334892400_hem2025000729C3","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1474-4422(16)30157-0","article-title":"Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"15","author":"Misawa","year":"2016","journal-title":"Lancet Neurol"},{"issue":"9","key":"2025120616334892400_hem2025000729C4","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2169\/internalmedicine.3800-19","article-title":"Lenalidomide treatment for thalidomide-refractory POEMS syndrome: a prospective single-arm clinical trial","volume":"59","author":"Suichi","year":"2020","journal-title":"Intern Med"},{"issue":"5","key":"2025120616334892400_hem2025000729C5","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/bjh.14966","article-title":"Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial","volume":"179","author":"Nozza","year":"2017","journal-title":"Br J Haematol"},{"issue":"2","key":"2025120616334892400_hem2025000729C6","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/bjh.19626","article-title":"An open-label, prospective trial to evaluate the efficacy and safety of ixazomib in combination with cyclophosphamide and dexamethasone in patients with newly diagnosed POEMS syndrome","volume":"205","author":"He","year":"2024","journal-title":"Br J Haematol"},{"issue":"7","key":"2025120616334892400_hem2025000729C7","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1182\/blood-2002-07-2299","article-title":"POEMS syndrome: definitions and long-term outcome","volume":"101","author":"Dispenzieri","year":"2003","journal-title":"Blood"},{"issue":"12","key":"2025120616334892400_hem2025000729C8","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/ajh.27081","article-title":"POEMS syndrome: update on diagnosis, risk-stratification, and management","volume":"98","author":"Dispenzieri","year":"2023","journal-title":"Am J Hematol"},{"key":"2025120616334892400_hem2025000729C9","doi-asserted-by":"crossref","first-page":"17562864231219151","DOI":"10.1177\/17562864231219151","article-title":"Efficacy of bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed POEMS syndrome patients","volume":"17","author":"Fang","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"2025120616334892400_hem2025000729C10","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/leu.2015.344","article-title":"Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment","volume":"30","author":"Kourelis","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"2025120616334892400_hem2025000729C11","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41375-019-0391-2","article-title":"What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone?","volume":"33","author":"Zhao","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"2025120616334892400_hem2025000729C12","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.bbmt.2018.01.026","article-title":"Efficacy and long-term outcomes of autologous stem cell transplantation in POEMS syndrome: a nationwide survey in Japan","volume":"24","author":"Kawajiri-Manako","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2025120616334892400_hem2025000729C13","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/leu.2017.27","article-title":"Impact of pretransplant induction therapy on autologous stem cell transplantation for patients with newly diagnosed POEMS syndrome","volume":"31","author":"Li","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2025120616334892400_hem2025000729C14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3324\/haematol.2016.148460","article-title":"High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation","volume":"102","author":"Cook","year":"2017","journal-title":"Haematologica"},{"issue":"11","key":"2025120616334892400_hem2025000729C15","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1007\/s00277-021-04609-6","article-title":"Bortezomib plus dexamethasone as first-line therapy for patients with POEMS syndrome","volume":"100","author":"Gao","year":"2021","journal-title":"Ann Hematol"},{"issue":"1","key":"2025120616334892400_hem2025000729C16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2013-03-487025","article-title":"Outcomes of patients with POEMS syndrome treated initially with radiation","volume":"122","author":"Humeniuk","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2025120616334892400_hem2025000729C17","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1136\/jnnp-2012-304874","article-title":"Ambiguous effects of anti-VEGF monoclonal antibody (bevacizumab) for POEMS syndrome","volume":"84","author":"Sekiguchi","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2025120616334892400_hem2025000729C18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood-2012-04-423178","article-title":"Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience","volume":"120","author":"D'Souza","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2025120616334892400_hem2025000729C19","doi-asserted-by":"crossref","first-page":"207.e1","DOI":"10.1016\/j.jtct.2023.11.001","article-title":"Long-term outcomes of autologous stem cell transplantation in patients with newly diagnosed POEMS syndrome","volume":"30","author":"Li","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2025120616334892400_hem2025000729C20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ajh.26422","article-title":"Characteristics and risk factors for thrombosis in POEMS syndrome: a retrospective evaluation of 230 patients","volume":"97","author":"Mellors","year":"2022","journal-title":"Am J Hematol"},{"issue":"4","key":"2025120616334892400_hem2025000729C21","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/00005792-199607000-00005","article-title":"Acute arterial obliteration: a new feature of the POEMS syndrome?","volume":"75","author":"Lesprit","year":"1996","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"2025120616334892400_hem2025000729C22","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ajh.24356","article-title":"Long-term outcome of patients with POEMS syndrome: an update of the Mayo clinic experience","volume":"91","author":"Kourelis","year":"2016","journal-title":"Am J Hematol"},{"issue":"5","key":"2025120616334892400_hem2025000729C23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1600-0609.2008.01037.x","article-title":"Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome","volume":"80","author":"Dispenzieri","year":"2008","journal-title":"Eur J Haematol"},{"issue":"11","key":"2025120616334892400_hem2025000729C24","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/jnnp.2008.150177","article-title":"Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome","volume":"79","author":"Kuwabara","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"2025120616334892400_hem2025000729C25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1600-0609.2009.01330.x","article-title":"Successful bortezomib-based treatment in POEMS syndrome","volume":"83","author":"Tang","year":"2009","journal-title":"Eur J Haematol"},{"issue":"11","key":"2025120616334892400_hem2025000729C26","first-page":"3776","article-title":"Long-term outcomes of newly diagnosed POEMS syndrome patients who received first-line lenalidomide- based therapy","volume":"109","author":"Gao","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"2025120616334892400_hem2025000729C27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-023-00859-x","article-title":"Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: the Mayo Clinic Experience","volume":"13","author":"Vaxman","year":"2023","journal-title":"Blood Cancer J."},{"issue":"1","key":"2025120616334892400_hem2025000729C28","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-018-0672-7","article-title":"Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma","volume":"11","author":"Xu","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"17","key":"2025120616334892400_hem2025000729C29","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1182\/blood-2011-06-362392","article-title":"The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome","volume":"118","author":"D'Souza","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2025120616334892400_hem2025000729C30","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10072-023-07064-5","article-title":"Regular assessment of serum vascular endothelial growth factor levels to monitor POEMS syndrome","volume":"45","author":"Gentile","year":"2024","journal-title":"Neurol Sci"},{"issue":"6","key":"2025120616334892400_hem2025000729C31","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/ajh.21707","article-title":"Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome","volume":"85","author":"Stankowski-Drengler","year":"2010","journal-title":"Am J Hematol"},{"issue":"8","key":"2025120616334892400_hem2025000729C32","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/jnnp.2005.081547","article-title":"A modified peripheral neuropathy scale: the overall neuropathy limitations scale","volume":"77","author":"Graham","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2025120616334892400_hem2025000729C33","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/leu.2016.168","article-title":"Prognostic study for overall survival in patients with newly diagnosed POEMS syndrome","volume":"31","author":"Wang","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"2025120616334892400_hem2025000729C34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41408-021-00540-1","article-title":"Treatment and outcomes of POEMS syndrome: changes in the past 20 years","volume":"11","author":"Yu","year":"2021","journal-title":"Blood Cancer J"},{"issue":"10","key":"2025120616334892400_hem2025000729C35","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41409-023-02047-8","article-title":"Treatment and outcome of second-line therapy for POEMS syndrome after autologous stem cell transplantation","volume":"58","author":"Li","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2025120616334892400_hem2025000729C36","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41375-024-02489-z","article-title":"Capillary leak phenotype as a major cause of death in patients with POEMS syndrome","volume":"39","author":"Lee","year":"2025","journal-title":"Leukemia"},{"issue":"7","key":"2025120616334892400_hem2025000729C37","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00277-010-1149-0","article-title":"Clinical characteristics and long-term outcome of patients with POEMS syndrome in China","volume":"90","author":"Li","year":"2011","journal-title":"Ann Hematol"},{"issue":"3","key":"2025120616334892400_hem2025000729C38","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3324\/haematol.2012.073031","article-title":"Pulmonary hypertension in POEMS syndrome","volume":"98","author":"Li","year":"2013","journal-title":"Haematologica"},{"key":"2025120616334892400_hem2025000729C39","article-title":"IL-6 is a highly prognostic biomarker for POEMS syndrome Leukemia","author":"Cook"},{"issue":"1","key":"2025120616334892400_hem2025000729C40","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/bjh.14497","article-title":"Successful treatment of newly diagnosed POEMS syndrome with reduced-dose bortezomib based regimen","volume":"181","author":"He","year":"2018","journal-title":"Br J Haematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/393\/2470200\/393dispenzieri.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/393\/2470200\/393dispenzieri.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:33:58Z","timestamp":1765056838000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/393\/556842\/POEMS-syndrome-diagnosis-treatments-and-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000729","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}